rolipram has been researched along with Heart Failure in 5 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The β-blockers carvedilol and metoprolol provide important therapeutic strategies for heart failure treatment." | 3.80 | Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium. ( Berk, E; Christ, T; Engel, A; Galindo-Tovar, A; Gillette, KT; Kaumann, AJ; Molenaar, P; Ravens, U, 2014) |
| "Enhanced arginine vasopressin levels are associated with increased mortality during end-stage human heart failure, and cardiac arginine vasopressin type 1A receptor (V1AR) expression becomes increased." | 3.80 | β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling. ( Barr, LA; Carter, RL; Cheung, JY; Coleman, RC; Feldman, AM; Gao, E; Grisanti, LA; Houser, SR; Koch, WJ; Li, X; Makarewich, CA; Myers, VD; Song, J; Tilley, DG; Troupes, CD; Yu, D; Zhu, W, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nomoto, Y | 1 |
| Takai, H | 1 |
| Ohno, T | 1 |
| Nagashima, K | 1 |
| Yao, K | 1 |
| Yamada, K | 1 |
| Kubo, K | 1 |
| Ichimura, M | 1 |
| Mihara, A | 1 |
| Kase, H | 1 |
| Orstavik, O | 1 |
| Ata, SH | 1 |
| Riise, J | 1 |
| Dahl, CP | 1 |
| Andersen, GØ | 1 |
| Levy, FO | 2 |
| Skomedal, T | 2 |
| Osnes, JB | 2 |
| Qvigstad, E | 1 |
| Molenaar, P | 1 |
| Christ, T | 1 |
| Berk, E | 1 |
| Engel, A | 1 |
| Gillette, KT | 1 |
| Galindo-Tovar, A | 1 |
| Ravens, U | 1 |
| Kaumann, AJ | 1 |
| Tilley, DG | 1 |
| Zhu, W | 1 |
| Myers, VD | 1 |
| Barr, LA | 1 |
| Gao, E | 1 |
| Li, X | 1 |
| Song, J | 1 |
| Carter, RL | 1 |
| Makarewich, CA | 1 |
| Yu, D | 1 |
| Troupes, CD | 1 |
| Grisanti, LA | 1 |
| Coleman, RC | 1 |
| Koch, WJ | 1 |
| Houser, SR | 1 |
| Cheung, JY | 1 |
| Feldman, AM | 1 |
| Hussain, RI | 1 |
| Aronsen, JM | 1 |
| Afzal, F | 1 |
| Sjaastad, I | 1 |
| Krobert, KA | 1 |
5 other studies available for rolipram and Heart Failure
| Article | Year |
|---|---|
Studies of cardiotonic agents. 8. Synthesis and biological activities of optically active 6-(4-(benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)- pyridazinone (KF15232).
Topics: Animals; Aorta; Calcium; Cardiotonic Agents; Cattle; Dogs; Guinea Pigs; Heart Failure; In Vitro Tech | 1996 |
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydraz | 2014 |
Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Cyclic Nucleotide Phosphodiesterases, Ty | 2014 |
β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Calcium Signaling; Cardiom | 2014 |
The functional activity of inhibitory G protein (G(i)) is not increased in failing heart ventricle.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Animals; Carbachol; Cardiotonic Agents; GTP-Binding Pro | 2013 |